Your browser doesn't support javascript.
loading
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena, Salvatore; Di Bartolomeo, Maria; Raghav, Kanwal; Masuishi, Toshiki; Loupakis, Fotios; Kawakami, Hisato; Yamaguchi, Kensei; Nishina, Tomohiro; Fakih, Marwan; Elez, Elena; Rodriguez, Javier; Ciardiello, Fortunato; Komatsu, Yoshito; Esaki, Taito; Chung, Ki; Wainberg, Zev; Sartore-Bianchi, Andrea; Saxena, Kapil; Yamamoto, Eriko; Bako, Emarjola; Okuda, Yasuyuki; Shahidi, Javad; Grothey, Axel; Yoshino, Takayuki.
Afiliación
  • Siena S; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Di Bartolomeo M; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Raghav K; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Masuishi T; Aichi Cancer Center Hospital, Aichi, Japan.
  • Loupakis F; Oncology Institute Veneto IOV-IRCCS, Padua, Italy.
  • Kawakami H; Kindai University Hospital, Osaka, Japan.
  • Yamaguchi K; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Nishina T; National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Fakih M; City of Hope Medical Center, Philadelphia, PA, USA.
  • Elez E; Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Rodriguez J; Department of Medical Oncology, Gastrointestinal Oncology Unit, Clínica Universidad de Navarra, University of Navarra, Navarra, Spain.
  • Ciardiello F; Università degli Studi della Campania Luigi Vanvitelli, Caserta, Italy.
  • Komatsu Y; Hokkaido University Hospital, Hokkaido, Japan.
  • Esaki T; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Chung K; Prisma Health Cancer Institute, Greenville, SC, USA.
  • Wainberg Z; UCLA Medical Center, Los Angeles, CA, USA.
  • Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Saxena K; Daiichi Sankyo, Basking Ridge, NJ, USA.
  • Yamamoto E; Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Bako E; Daiichi Sankyo, Basking Ridge, NJ, USA.
  • Okuda Y; Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Shahidi J; Daiichi Sankyo, Basking Ridge, NJ, USA.
  • Grothey A; West Cancer Center, Germantown, TN, USA.
  • Yoshino T; National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp.
Lancet Oncol ; 22(6): 779-789, 2021 06.
Article en En | MEDLINE | ID: mdl-33961795
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Receptor ErbB-2 / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Receptor ErbB-2 / Inmunoconjugados / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia